<DOC>
	<DOCNO>NCT03043950</DOCNO>
	<brief_summary>A safety efficacy study first line therapy Vectibix® combination irinotecan , 5‑fluorouracil , folinic acid ( FOLFIRI ) validate prognostic score adult patient RAS wild-type metastatic colorectal cancer real world setting ( VALIDATE )</brief_summary>
	<brief_title>Validation New Prognostic Score Adult Patients With RAS Wild-type mCRC Treated With Vectibix® FOLFIRI First Line ( VALIDATE )</brief_title>
	<detailed_description>This non-interventional , prospective , open-label , single-arm , 3-cohort , multicenter study Germany . In total , 1,240 patient enrol 100 oncological site ( office-based medical oncologist , oncology outpatient-centers , university hospital ) time period 36 month . Of , 420 patient high risk , 420 patient intermediate risk , 400 patient low risk , priori assess metastatic colorectal cancer prognostic score ( mCCS ) , include . Overall survival pre-defined prognostic group analyze primary endpoint validate mCCS . Patients schedule receive first line combination therapy panitumumab FOLFIRI accord German regulation current German SmPC . Data efficacy term tumor response evaluation / survival safety ( ADRs ) collect first line therapy . A subset patient participate 'VALIDATE-PRO ' project ( n=620 ; 75 site ) assess general health-related quality life patient questionnaire . Biomarker status beyond RAS collect baseline . The documentation define patient data include survival continue end individual study participation late 36 month last patient . The end study late 36 month last patient ( LPI ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Eligibility accord current SmPC Signed write informed consent Diagnosis RASWT mCRC No prior systemic therapy palliative set Aged 18 year old Any contraindication accord current SmPC Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mCRC</keyword>
	<keyword>First line</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>mCCS Prognostic Score</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Ras wild type</keyword>
</DOC>